Details of the Drug Reposition

General Information of This Drug (ID: DMF3GM2)

Drug Name
Somatropin recombinant   DMF3GM2
Synonyms Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN)
Therapeutic Class
Hormone Replacement Agents

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Turner syndrome DIS2035C N.A. Approved [1]
Pituitary dwarfism DISI019B N.A. Approved [2]
Growth hormone deficiency DIS8BMO7 5A61.3 Approved [3]
Fetal growth restriction DIS5WEJ5 KA20.1Z Approved [4]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prader-Willi syndrome DISYWMLU LD90.3 Withdrawn [5]
------------------------------------------------------------------------------------

References

1 The use of somatropin (recombinant growth hormone) in children of short stature. Paediatr Drugs. 2002;4(1):37-47.
2 Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2717-e2728.
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol. 2017 Feb;13(2):105-124.
5 Study to Evaluate Arikace?in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa